A competitor recently earned FDA approval, but this drug is reportedly going to be pricey.An analyst's very bullish new research note was the spark that lit a fire under the stock of Vera Therapeutics (VERA +12.88%) on Tuesday. That extremely positive investor reaction boosted the share price of the clinical-stage biotech by almost 13% on the day. Price advantage?The analyst in question was Ryan Deschner of Raymond James, who reiterated his strong buy recommendation on Vera stock. He also maintained his $73 ...